NIH FUNDS PUBLIC PRIVATE PARTNERSHIP – The National Institutes of Health is funding ten drug companies and seven non-profit organizations to collaborate in research seeking breakthroughs in Alzheimer’s disease, Type 2 diabetes, rheumatoid arthritis and lupus. The $230 million five year program requires participates to share data in regular conference calls and meetings to share findings in […]
HCS provides comprehensive disease state training and education for professionals in the fields of public health, medicine, pharmaceutical science, health policy, communications, and education. HCS curricula cover the scientific and policy aspects of emerging and long standing infectious diseases and chronic health conditions. These include: historical origins, etiology, epidemiology, scientific and clinical developments/discoveries, to current treatment of disease and disease state co-morbidities.
HEALTH CLEAR NEWS
-
February 5, 2014
-
January 8, 2014
FDA APPROVES FIRST NUCLEOTIDE INHIBITOR TO TREAT HCV – The US Food and Drug Administration (FDA) approved the first- nucleotide analog inhibitor sofosbuvir, brand named – Sovaldi – to treat adults with chronic Hepatitis C infection, genotypes (GT) 1-4. For patients with chronic HCV 2 and 3 the great news is that treatment with sofosbuvir […]
-
CHIKUNGUNYA ARRIVES IN THE CARIBBEAN – On December 13, 2013, the New York Times reported that Chikungunya, a virus transmitted by the Tiger mosquito — and endemic to Africa, India and South East Asia — has appeared for the first time in the Caribbean, on the island of St. Martin. Chikungunya, translated as “that which […]
